


3-2-07

PTO/SB/21 (09-04)


Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1644

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM  Total Number of Pages in This Submission	Application Number	10/516,837
	Filing Date	August 9, 2005
	First Named Inventor	Robert Paul Anderson
	Art Unit	1644
	Examiner Name	Nora Maureen Rooney
	Attorney Docket Number	BTG0008-101 (142769US01)

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached/Authorized <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Filing <input type="checkbox"/> Affidavits / declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Supplementary Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Forms PTO SB/08a and SB/08b (9 pp.); (105) References Cited; (81) Reference Copies Submitted; Return Card.
Remarks EXPRESS MAIL LABEL NO. : EV 770972316 US DATE OF DEPOSIT : FEBRUARY 28, 2007		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm	Cozen O'Connor		
Signature			
Printed Name	Paul K. Legaard, Ph.D.		
Date	February 28, 2007	Reg. No.	38,534

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Signature			
Typed or printed name		Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

BTG0008-101 (142769US01)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

On re application of: **Robert Anderson et al.**

Serial No.: **10/516,837**

Group Art Unit: **1644**

Filing Date: **August 9, 2005**

Examiner: **Nora Maureen Rooney**

Title: **Therapeutic Epitope and Uses Thereof**

EXPRESS MAIL LABEL NO : EV 770972316
DATE OF DEPOSIT : February 28, 2007

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO Forms SB/08A and SB/08B, formerly known as PTO Form 1449 submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

This Information Disclosure Statement is being filed:

- ☐ within three months of the filing date of the patent application.
- ☐ within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 of the international application.
- ☒ **before** the mailing date of a first Office Action on the merits.
- ☐ **after** the mailing date of a first Office Action on the merits, but before the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, and accordingly is accompanied by:

☐ the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below);

or

☐ the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or

☐ No fee is owed by the applicant(s).

☐ In accordance with 37 C.F.R. § 1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below) and the fee of \$180.00 as set forth in 37 C.F.R. § 1.17(p), is attached.

☐ after the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, but before the payment of the Issue Fee, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e), (see "Statement," and "Fees" below).

☒ Copies of the references (except the U.S. Patent documents) listed on the attached PTO Forms SB/08A and SB/08B, formerly known as PTO Form 1449 are enclosed.

EXCEPT THAT:

☐ In view of the voluminous nature of references, and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ In accordance with 37 C.F.R. § 1.98(d), copies of all references listed on the attached PTO Forms SB/08A and SB/08B, formerly known as PTO Forms 1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application _____ for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.

☐ If the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Statement under 37 C.F.R. § 1.97(e)

- ☐ The undersigned attorney hereby states that each item information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.


Fees

- ☒ No Fee is owed by the applicant(s).
- ☐ The Information Disclosure Statement Fee of \$180.00 under 37 C.F.R. § 1.17(p) is enclosed herewith.

Method of Payment of Fees

- ☐ Attached is a check in the amount of \$_____. This form is submitted in duplicate.
- ☐ Charge Deposit Account No. 50-1275 in the amount of \$180.00. This form is submitted in duplicate.
- ☒ Please charge any deficiency or credit any overpayment to Deposit Account 50-1275.
- ☐ No fee or Statement is required under 37 C.F.R. § 1.97(b).

Respectfully submitted,


Paul K. Legaard, Ph.D.
Registration No. 38,534

Dated: February 28, 2007

COZEN O'CONNOR, P.C.
1900 Market Street, 5th Floor
Philadelphia, PA 19103-3508
(215) 665-2000 – Telephone
(215) 701-2013 - Facsimile

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 9

Complete if Known

Application Number	10/516,837
Filing Date	August 9, 2005
First Named Inventor	Robert Paul Anderson
Art Unit	1644
Examiner Name	Nora Maureen Rooney
Attorney Docket Number	BTG0008-101 (142769US01)

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication/Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	AA	US- 4,710,461	12/01/1987	Komano et al	
	AB	US- 4,886,753	12/12/1989	Marcker et al	
	AC	US- 4,943,674	07/24/1990	Houck et al	
	AD	US- 5,086,169	02/04/1992	Mascarenhas	
	AE	US- 5,097,025	03/17/1992	Benfey et al	
	AF	US- 5,107,065	04/21/1992	Shewmaker et al	
	AG	US- 5,110,732	05/05/1992	Benfey et al	
	AH	US- 5,187,267	02/16/1993	Comai et al	
	AI	US- 5,202,257	04/13/1993	Heinemann et al	
	AJ	US- 5,250,515	10/05/1993	Fuchs et al	
	AK	US- 5,356,799	10/18/1994	Fabijanski et al	
	AL	US- 5,428,146	06/27/1995	Logemann et al	
	AM	US- 5,459,252	10/17/1995	Conkling et al	
	AN	US- 5,495,007	02/27/1996	Thompson et al	
	AO	US- 5,589,583	12/31/1996	Klee et al	
	AP-	US- 5,589,610	12/31/1996	De Beuckeleer et al	
	AQ	US- 5,618,988	04/08/1997	Hauptmann et al	
	AR	US- 5,629,183	05/13/1997	Saunders et al	
	AS	US- 5,633,363	05/27/1997	Colbert et al	
	AT	US- 5,646,333	07/08/1996	Dobres et al	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	AU	WO98/56811	12/17/98	Consejo Superior De Investigaciones Cientificas		
	AV	WO99/58681	11/18/99	Consejo Superior De Investigaciones Certi		
	AW	WO97/47745	12/18/97	Consejo Superior De Investigaciones Certificas		
	AX	WO97/20058	06/05/97	Bay Zoltan Alkalmazott Kutatasi Alapitva		
	AY	EP 905 236	03/31/99	Med. Res. Council		
	AZ	WO99/53075	10/21/99	Du Pont		
	BA	WO00/47614	08/17/00	Pioneer Hi Bred Int.		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered; whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 9

Complete if Known

Application Number	10/516,837
Filing Date	August 9, 2005
First Named Inventor	Robert Paul Anderson
Art Unit	1644
Examiner Name	Nora Maureen Rooney
Attorney Docket Number	BTG0008-101 (142769US01)

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication/Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	AA	US- 4,710,461	12/01/1987	Komano et al	
	AB	US- 4,886,753	12/12/1989	Marcker et al	
	AC	US- 4,943,674	07/24/1990	Houck et al	
	AD	US- 5,086,169	02/04/1992	Mascarenhas	
	AE	US- 5,097,025	03/17/1992	Benfey et al	
	AF	US- 5,107,065	04/21/1992	Shewmaker et al	
	AG	US- 5,110,732	05/05/1992	Benfey et al	
	AH	US- 5,187,267	02/16/1993	Comai et al	
	AI	US- 5,202,257	04/13/1993	Heinemann et al	
	AJ	US- 5,250,515	10/05/1993	Fuchs et al	
	AK	US- 5,356,799	10/18/1994	Fabijanski et al	
	AL	US- 5,428,146	06/27/1995	Logemann et al	
	AM	US- 5,459,252	10/17/1995	Conkling et al	
	AN	US- 5,495,007	02/27/1996	Thompson et al	
	AO	US- 5,589,583	12/31/1996	Klee et al	
	AP-	US- 5,589,610	12/31/1996	De Beuckeleer et al	
	AQ	US- 5,618,988	04/08/1997	Hauptmann et al	
	AR	US- 5,629,183	05/13/1997	Saunders et al	
	AS	US- 5,633,363	05/27/1997	Colbert et al	
	AT	US- 5,646,333	07/08/1996	Dobres et al	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	AU	WO98/56811	12/17/98	Consejo Superior De Investigaciones Cientificas		
	AV	WO99/58681	11/18/99	Consejo Superior De Investigaciones Certi		
	AW	WO97/47745	12/18/97	Consejo Superior De Investigaciones Certificas		
	AX	WO97/20058	06/05/97	Bay Zoltan Alkalmazott Kutatasi Alapitva		
	AY	EP 905 236	03/31/99	Med. Res. Council		
	AZ	WO99/53075	10/21/99	Du Pont		
	BA	WO00/47614	08/17/00	Pioneer Hi Bred Int.		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered; whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 9

Complete if Known

Application Number	10/516,837
Filing Date	August 9, 2005
First Named Inventor	Robert Paul Anderson
Group Art Unit	1644
Examiner Name	Nora Maureen Rooney
Attorney Docket Number	BTG0008-101 (142769US01)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
	BF	Ach, et al., "RRB1 and RRB2 encode maize retinoblastoma-related proteins that interact with a plant D-type cyclin and geminivirus replication protein," Mol. Cell Biol. (1997) 17:5077-5086.	
	BG	Albani, et al., "DcE2F, a functional plant E2F-like transcriptional activator from Daucus carota," J. Biol. Chem. (2000) 275:19258-19267	
	BH	Bandara, et al., "Functional synergy between DP-1 and E2F-1 in the cell cycle-regulating transcription factor DRTF1/E2F," EMBO J. (1993) 12:4317-4324.	
	BI	Bogre, et al., "Wounding induces the rapid and transient activation of a specific MAP kinase activity," Plant Cell (1997) 9:75-83.	
	BJ	Breeden and Nasmyth, "Regulation of the yeast HO gene," Cold Spring Harbor Symp. Quant. Biol. (1985) 50:643-650.	
	BK	Breeden, "Start-specific transcription in yeast," Curr. Topics Microbiol. Immunol. (1996) 208:95-127.	
	BL	de Jager, et al., "Retinoblastoma proteins implants," Plant Mol. Biol. (1999) 41:295-299.	
	BM	de la Luna, et al., "Nuclear accumulation of the E2F heterodimer regulated by subunit composition and alternative splicing of a nuclear localization signal," J. Cell Sci. (1996) 109:2443-2452.	
	BN	Denecke, et al., "Plant and mammalian sorting signals for protein retention in the endoplasmic reticulum contain a conserved epitope," EMBO J. (1992) 11:2345-2355	
	BO	Doonan and Folbert, "Conserved and novel regulators of the plant cell cycle," Curr. Opin. Cell Biol. (1997) 9:824-830.	
	BP	Dynlacht B.D. et al., "DNA-binding and trans-activation properties of Drosophila E2F and DP proteins," Proc Natl Acad Sci U S A 1994 Jul 5;91(14):6359-63.	


Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 9

Complete if Known

Application Number	10/516,837
Filing Date	August 9, 2005
First Named Inventor	Robert Paul Anderson
Group Art Unit	1644
Examiner Name	Nora Maureen Rooney
Attorney Docket Number	BTG0008-101 (142769US01)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BQ	Dyson, "The regulation of E2F by pRB-family proteins," Genes Dev. (1998) 12:2245-2262.	
	BR	Fields and Song, "A novel genetic system to detect protein-protein interactions," Nature (1989) 340:245-246.	
	BS	Fountain, et al., "Isolation and characterization of a plant retinoblastoma-related gene from photoautotrophic cell suspension culture of <i>Chenopodium rubrum</i> L.," Plant Physiol. (1999) 119:363.	
	BT	Fuerst, et al., "Modulation of cyclin transcript levels in cultured cells of <i>Arabidopsis thaliana</i> ," Plant Physiol. (1996) 112:1023-1033.	
	BU	Gillaspay G.E. et al., GenBank Accession No. U39059, 18 November 1996	
	BV	Gillespie D. "The magic and challenge of DNA probes as diagnostic reagents," <i>Vet Microbiol</i> (1990), (3)	
	BW	Girling, et al., "A new component of transcription factor DRTF1/E2F," Nature (1993) 362:83-87.	
	BX	Graft, et al., "A maize cDNA encoding a member of the retinoblastoma protein family: involvement in endoreduplication," Proc. Natl. Acad. Sci. USA (1996) 93:8962-8967.	
	BY	Gutierrez, "DNA replication and cell cycle in plants: learning from geminiviruses," EMBO J. (2000) 19:792-799.	
	BZ	Gutierrez, "The retinoblastoma pathway in plant cell cycle and development," Curr. Opin. Plant Biol. (1998) 1:492-497.	
	CA	Hiebert S.W. et al., "E2F-1: DP-1 induces P53 and overrides survival factors to trigger apoptosis," Mol Cell Biol (1995), 15(12): 6864-74.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 9

Complete if Known

Application Number	10/516,837
Filing Date	August 9, 2005
First Named Inventor	Robert Paul Anderson
Group Art Unit	1644
Examiner Name	Nora Maureen Rooney
Attorney Docket Number	BTG0008-101 (142769US01)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS


Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CB	Helin, et al., "Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative trans-activation," Genes Dev. (1993) 7:1850-1861.	
	CC	Helin, et al., "Inhibition of E2F-1 trans-activation by direct binding of the retinoblastoma protein," Mol. Cell Biol. (1993) 13:6501-6508.	
	CD	Helin, et al., A cDNA encoding a pRB-binding protein with properties of the transcription factor E2F," Cell (1992) 70:337-350.	
	CE	Huntley and Murray, "The plant cell cycle," Curr. Opin. Plant Biol. (1999) 2:440-446.	
	CF	Huntley, et al., "The maize retinoblastoma protein homologue ZmRb1 is regulated during leaf development and display conserved interactions with G1/S regulators and plant cyclins (D-type) proteins," Plant Mol. Biol. (1998) 37:155-169.	
	CG	Kosugi and Obashi, "PCF1 and PCF2 specifically bind to cis elements in the rice proliferating cell nuclear antigen gene," Plant Cell (1997) 9:1607-1619.	
	CH	Kozak, "At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cell," J Mol Biol (1987), 196:947-950.	
	CI	Krek, et al., "Binding to DNA and the retinoblastoma gene product promoted by complex formation of different E2F family members," Science (1993) 262:1557-1560	
	CJ	Lipman, et al., "Rapid and sensitive protein similarity searches," Science (1985) 227:1435-1441	
	CK	Lowndes, et al., "Control of DNA synthesis genes in fission yeast by the cell cycle gene cdc10," Nature (1992) 355:449-453.	
	CL	Lui, et al., "The Aradiopsis Cdc2a-interacting protein ICK2 is structurally related to ICK1 and is a potent inhibitor of cyclin-dependent kinase activity in vitro," Plant J. (2000) 21:379-386.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 6 of 9

Complete if Known

Application Number	10/516,837
Filing Date	August 9, 2005
First Named Inventor	Robert Paul Anderson
Group Art Unit	1644
Examiner Name	Nora Maureen Rooney
Attorney Docket Number	BTG0008-101 (142769US01)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CM	Magyar Z. et al., "Characterization of two distinct DP-related genes from Arabidopsis thaliana," <i>FEBS Lett.</i> 2000 Dec 1; 486(1):79-87.	
	CN	Mariconti L. et al., "The E2F family of transcription factors from Arabidopsis thaliana. Novel and conserved components of the retinoblastoma/E2F pathway in plants," <i>J Biol Chem</i> (2002), 277(12):9911-9. Epub 2002 Jan 10.	
	CO	Martinez-Balbos, et al., "Regulation of E2F1 activity by acetylation," <i>EMBO J.</i> (2000) 19:662-671.	
	CP	Marzio, et al., "E2F family members are differently regulated by reversible acetylation," <i>J. Biol. Chem.</i> (2000) 275:10887-10892.	
	CQ	Mironov, et al., "Cyclin-dependent kinases and cell division in plants: the nexus," <i>Plant Cell</i> (1999) 11:509-521.	
	CR	Nakagami, et al., "Tobacco retinoblastoma-related protein phosphorylated by a distinct cyclin-dependent kinase complex with Cdc2/cyclin D in vitro," <i>Plant J.</i> (1999) 18:243-252.	
	CS	Nevins, "E2F: A link between the Rb tumor suppression protein and viral oncoproteins," <i>Science</i> (1992) 258:424-429.	
	CT	Ormonroyd, et al., "A new member of the DP family, DP-3, with distinct protein products suggests regulatory role for alternative splicing in the cell cycle transcription factor DRTF1/E2F," <i>Oncogene</i> (1995) 11:1437-1446.	
	CU	Othani and Nevins, "Functional properties of a Drosophila homolog of the E2F-1 gene," <i>Mol. Cell Biol.</i> (1994) 14:1603-1612	
	CV	Ouelette, et al., (TITLE UNKNOWN) <i>Oncogene</i> (1992) 7:1075-1081	
	CW	Ramirez-Parra, et al., "Characterization of wheat DP, a heterodimerization partner of the plant E2F transcription factor which stimulates E2F-DNA binding," <i>FEBS Lett.</i> (2000) 486:73-78.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 7 of 9

Complete if Known

Application Number	10/516,837
Filing Date	August 9, 2005
First Named Inventor	Robert Paul Anderson
Group Art Unit	1644
Examiner Name	Nora Maureen Rooney
Attorney Docket Number	BTG0008-101 (142769US01)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CX	Ramirez-Parra, et al., "The cloning of plant E2F, a retinoblastoma-binding protein, reveals unique and conserved features with animal G1/S regulators," Nucl. Acids, Res. (1999) 27:3527-3533.	
	CZ	Riou-Kamlichi, et al., "Cytokinin activation of Aradiopsis cell division through a D-type cyclin," Science (1999) 283:1541-1544.	
	DA	Sandler SJ et al., "Inhibition of gene expression in transformed plants by antisense RNA," Plant Molecular Biology (1988), 11(3): 301-310.	
	DB	Sanford, et al., "Optimizing the biolistic process for diffesent biological applications," Methods Enzymol. (1993) 217:483-509.	
	DC	Sardet, et al., "E2F-4 and E2F-5, to members of the E2F family, are expressed in the early phases of the cell cycle," Proc. Natl. Acad. Sci. USA (1995) 92:2403-2407.	
	DD	Sawado T et al., "dE2F2, a novel E2F-family transcription factor in Drosophila melanogaster," Biochem Biophys Res Coimmun 1998 Oct 20;251(2):409-415.	
	DE	Scott, et al, "Model system for plant cell biology: GFP imaging in living onion epidermal cells," Biotechniques (1999) 26:1125-1132	
	DF	Sekine, et al., "Isolation and characterization of the E2F-like gene in plants," FEBS Lett. (1999) 460:117-122.	
	DG	Shoemaker, et al., EMBL Acc. No. AI939068, August 3, 1999	
	DH	Slansky and Farnum, "Introduction to the E2F family: protein structure and gene reguation," Curr. Topics Microbiol. Immunol. (1996) 208:1-30.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

8

of

9

Complete if Known

Application Number	10/516,837
Filing Date	August 9, 2005
First Named Inventor	Robert Paul Anderson
Group Art Unit	1644
Examiner Name	Nora Maureen Rooney
Attorney Docket Number	BTG0008-101 (142769US01)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS


Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	DI	Smith and Waterman, "Comparison of biosequences", Adv. Mathematics (1981) 2:482-489.	
	DJ	Suarez-Lopez and Gutierrez, "DNA replication of wheat dwarfgeminivirus vectors: effects of origin structure and size," Virology (1997) 227:389-399.	
	DK	Tao, et al., "Subunit composition determines E2F DNA-binding site specificity," Mol. Cell Biol. (1997) 17:6994-7007	
	DL	Umada, et al., "A distinct cyclin-dependent kinase-activating kinase of Arabidopsis thaliana," Proc. Natl. Acad. Sci. USA (1998) 95:5021-5026	
	DM	Van der Krol A.R. et al., "Inhibition of flower pigmentation by antisense CHS genes: promoter and minimal sequences requirements for antisense effect," Plant Mol Biol (1990), 14(4): 457-466.	
	DN	Varagona, et al., "Nuclear localization signal(s)-required for nuclear targeting of the maize regulatory protein Opaque-2," Plant Cell (1992) 4:1213-1227	
	DO	von Armin et al., "Cloning vectors for expression of green fluorescent protein fusion proteins in transgenic plants," Gene (1998) 221:35-43.	
	DP	von Armin, et al., "Light inactivation of Arabidopsis photomorphogenic repressor COP1 involves a cell-specific regulation of its nucleocytoplasmic partitioning," Cell (1994) 79:1035-1045	
	DQ	Wang, et al., "ICK1, a cyclin-dependent protein kinase inhibitor from Arabidopsis thaliana interacts with both cdc2a and CycD3, and its expression is induced by abscisic acid," Plant J. (1998) 15:501-510.	
	DR	Waterhouse et al., "Virus resistance and gene silencing: killing the messenger," Trends Plant Sci. (1999), 4(11): 452-457.	
	DS	Whisstock J.C. et al., "Prediction of protein function from protein sequence and structure," Q Rev Biophys (2003) 36(3):307 Review.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 9 of 9

Complete if Known

Application Number	10/516,837
Filing Date	August 9, 2005
First Named Inventor	Robert Paul Anderson
Group Art Unit	1644
Examiner Name	Nora Maureen Rooney
Attorney Docket Number	BTG0008-101 (142769US01)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	DT	Wu CL et al., "In vivo association of E2F-family transcription factor in Drosophila melanogaster," <i>Mol Cell Biol</i> (1995); 15(5): 2536-46.	
	DU	Xie, et al., "GRAB proteins, novel members of the NAC domain family, isolated by their interaction with a geminivirus protein," <i>Plant Mol. Biol.</i> (1999) 39:647-656.	
	DV	Xie, et al., "Identification and analysis of a retinoblastoma binding motif in the replication protein of a plant DNA virus: requirement for efficient viral DNA replication," <i>EMBO J.</i> (1995) 14:4073-4082.	
	DW	Xie, et al., "Plant cells contain a novel member of the retinoblastoma family of growth regulatory proteins," <i>EMBO J.</i> (1996) 15:4900-4908.	
	DX	Zheng, et al., "Structural basis of DNA recognition by the heterodimeric cell cycle transcription factor E2F-DP," <i>Genes Dev.</i> (1999) 13:666-674.	
	DY	Fleckenstein "Gliadin T cell epitope selection by tissue transglutaminase in celiac disease. Role of enzyme specificity and pH influence on the transamidation versus deamidation process," <i>J Biol Chem</i> (2002) 277(37):34109-34116.	
	DZ	Fraser et al., "Coeliac disease: In vivo toxicity of the putative immunodominant epitope," <i>Gut</i> (2003) 52(12):1698-1702.	
	EA	Lundin et al., "Oats induced villous atrophy in coeliac disease," <i>Gut</i> (2003) 52(11):1649-1652.	
	EB	van de Wal, "Glutenin is involved in the gluten-driven mucosal T cell response," <i>Eur J Immunol</i> (1999) 29(10):3133-3139.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.